Business Context and Reporting Period
This Form 8-K is a current report filed by Rexahn Pharmaceuticals, Inc. (not Opus Genetics, Inc.) on November 22, 2016. The filing addresses corporate governance matters, specifically the scheduling of the 2017 Annual Meeting of Stockholders and the deadlines for shareholder proposals.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to corporate governance notifications and contains no financial performance data.
Material Changes
There are no material financial changes reported. The primary event is the administrative setting of the 2017 Annual Meeting date to April 11, 2017.
Guidance, Outlook, and Management Commentary
- Shareholder Proposals: Proposals for inclusion in proxy materials must be received by December 19, 2016.
- Advance Notice Proposals: Proposals intended for presentation at the meeting (but not included in proxy materials) must be received between December 12, 2016 and January 11, 2017.
- Location: The Company's principal executive offices are located in Rockville, Maryland.
Key Facts for Investor Verification
- Verify the correct registrant name is Rexahn Pharmaceuticals, Inc., as the input metadata referenced Opus Genetics, Inc.
- Confirm the 2017 Annual Meeting date is set for April 11, 2017.
- Note the strict deadlines for submitting shareholder proposals: December 19, 2016 for proxy inclusion and January 11, 2017 for advance notice proposals.
- Recognize that this filing contains no financial results or operational updates.